Olaratumab information

Olaratumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	PDGF-R α
Clinical data
Trade names	Lartruvo
Other names	IMC-3G3, LY-3012207
AHFS/Drugs.com	Monograph
License data	US DailyMed: Lartruvo;
Routes of; administration	Intravenous infusion
ATC code	L01FX10 (WHO) ;
Legal status
Legal status	CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Protein binding	None
Metabolism	Proteolytic enzymes
Elimination half-life	11 days
Identifiers
CAS Number	1024603-93-7 ;
DrugBank	DB06043 ;
ChemSpider	None;
UNII	TT6HN20MVF;
KEGG	D09939 ;
Chemical and physical data
Formula	C6554H10076N1736O2048S40
Molar mass	147241.21 g·mol−1
	(what is this?) (verify)

Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.^[2]

It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses").

^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
^ "Statement on a Nonproprietary name adopted by the USAN Council: Olaratumab" (PDF). Archived from the original (PDF) on 15 August 2016. Retrieved 18 March 2010.

[1] "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.

[2] "Statement on a Nonproprietary name adopted by the USAN Council: Olaratumab" (PDF). Archived from the original (PDF) on 15 August 2016. Retrieved 18 March 2010.

Olaratumab information

and 24 Related for: Olaratumab information

Olaratumab

Dexamethasone

Testosterone

Insulin

Amitriptyline

Erythropoietin

Elranatamab

Nomenclature of monoclonal antibodies

Daratumumab

Nerve growth factor

Osimertinib

Trastuzumab deruxtecan

Epidermal growth factor

HER2

List of drugs granted breakthrough therapy designation

Nintedanib

Cerebrolysin

Alectinib

Cetuximab

List of human clusters of differentiation

Bevacizumab

Imatinib

Cabozantinib

Epidermal growth factor receptor